The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: ##STR00001## The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: ##STR00001## The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein L.sub.1. L.sub.2, L.sub.3, L.sub.4, L.sub.5, L.sub.6, L.sub.7, L.sub.8, L.sub.9, L.sub.10, Y.sub.1,Y.sub.2, Y.sub.3, Y.sub.4, R.sub.1, R.sub.2, R.sub.3 , R.sub.4, R.sub.5, R.sub.6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein L.sub.1. L.sub.2, L.sub.3, L.sub.4, L.sub.5, L.sub.6, L.sub.7, L.sub.8, L.sub.9, L.sub.10, Y.sub.1,Y.sub.2, Y.sub.3, Y.sub.4, R.sub.1, R.sub.2, R.sub.3 , R.sub.4, R.sub.5, R.sub.6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

Chromogenic substrates for -D-glucuronidase activity comprising monoglucuronides of some 1,2-dihydroxyaromatic derivatives. When cleaved these form soluble colored conjugates with multivalent metal ions such as iron ions. The substrates may be used in conjunction with chromogenic substrates for other enzymes in microbial detection and identification especially involving liquid media. Microbes can be grown in the presence of the substrates and the compounds providing the metal ion. The substrates are particularly useful for detecting -D-glucuronidase-positive E. coli. Synthetic methods for making the compounds are described.

Chromogenic substrates for -D-glucuronidase activity comprising monoglucuronides of some 1,2-dihydroxyaromatic derivatives. When cleaved these form soluble colored conjugates with multivalent metal ions such as iron ions. The substrates may be used in conjunction with chromogenic substrates for other enzymes in microbial detection and identification especially involving liquid media. Microbes can be grown in the presence of the substrates and the compounds providing the metal ion. The substrates are particularly useful for detecting -D-glucuronidase-positive E. coli. Synthetic methods for making the compounds are described.

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein L.sub.1, L.sub.2, L.sub.3, L.sub.4, L.sub.5, L.sub.6, L.sub.7, L.sub.8, L.sub.9, L.sub.10, Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein L.sub.1, L.sub.2, L.sub.3, L.sub.4, L.sub.5, L.sub.6, L.sub.7, L.sub.8, L.sub.9, L.sub.10, Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

The present invention encompasses compounds and methods for treating urinary tract infections.

The present invention encompasses compounds and methods for treating urinary tract infections.